Literature Review on Lung Cancer and Rheumatoid Arthritis

S.No Authors name Paper title Journal name Year of publication Key finding/Remarks

Alan J Silman and Jacqueline E Pearson Epidemiology and genetics of rheumatoid arthritis Arthritis research and therapy 9 May 2002 This article consider and purposes the direct and indirect evidence to the contribution of various risk factor for disease sucessibility.we conclude that genetic risk factor for RA is the HLA DRB1 alleles, and tumour necrosis, non MHC genes, environmental factors, parvovirus and mycoplasma.

Fredrick Wolf, Donald M. Mitchell, John T.

Sibley, James F. Fries, Daniel A. Bloch, Catherine A. Williams, Patricia W. Spitz, May Haga, Sue M. Kleinheksel, and Mary Ann Cathey The mortality of Rheumatoid arthritis British Journal of Industrial medicine 10 August 1955 In this article, the author determines the risk and causes of death and to quantify mortality predictors in patient with RA.

Get quality help now

Sweet V

Verified

Proficient in: Cancer

4.9 (984)

“ Ok, let me say I’m extremely satisfy with the result while it was a last minute thing. I really enjoy the effort put in. ”

+84 relevant experts are online

Hire writer

This study shows that mortality rate are increase at least two fold in RA and are linked to clinically severity to cardiovascular and cerebrovascular disease

Thomas J Oligino, Stacie A Dairymple Targeting B cells for the treatment of Rheumatoid arthritis(RA) Arthritis Res There 2003 In this article the author describes the role of B cells for the treatment of RA.

This article shows that activation and development of B cells has a number of possible therapeutic target that are appealing for drug target

Larry W Morrland, Michael H Schiff, Scott W Raumaqarter. Elizabeth A Tindall. Rov M Etanercept therapy in RA; a randomized controlled trial Annals of internal medicine 1999 This paper confirms the benefit of etanercept therapy of longer duration and simplified dosing in patient with RA. This concludes that etanercept can safely provide rapid, significant and sustained benefit in patient with active RA.

Cynthia S Crowson, MS, Katherine P Liao, MD MPH and Sherine E Gabriel, MD MSC Rheumatoid arthritis and cardiovascular disease American heart Journal 2013 In this article the author describes that RA is most common of rheumatid diseases and shows the best relationship with heart disease. We conclude from this article that the treatment of RA patients have an increase risk of developing heart diseases via by using steroid and suppressing inflammation.

Ewa M Paleolog Angiogenesis in Rheumatoid arthritis Arthritis Research and Therapy 2002 In this article the author focuses on regulation of angiogenesis in RNA, application of angiogenesis inhibitor. We conclude that at least, angiogenic treatment should not potentially increase the risk of infection and combination of anti-VEGF and infliximab in RA may be beneficial without adverse effects.

Chenglong Han, Don W Robinson, Monica V Hackett. L Clark Paramore Kathy H Fraeman Cardiovascular disease and risk factors in patient with RA, psoriatic arthritis and ankylosing spodylitis The Journal of rheumatology 2006 In this article the author compare the prevalence of cardiovascular disease and their risk factor between patient with RA, psoriatic arthritis and ankylosing spondylitis and control subjects. We conclude that RA, psoriatic ankylosing (PsA), and ankylosing spondylitis (AS). Use of angiotensin converting enzyme inhibitor, calcium channel blockers, and anticoagulants are significantly higher in patient than control.

C Copper, C Coupland and M Mitchell RA, corticosteroid therapy and hip fracture Annal of rheumatoid diseases 1995 In this article, author discuss that hip fracture risk is approximately double amongst RA patient and among those who are taking steroid.

Peter E Lipsky, Desiree MFM van der Heijde, E William St. Clair. Daniel E Furst Ferdinand C Infliximab and methotrexate in the treatment of RA New England Journal of Medicine 2000 In this article the author describes the quality of life is also significantly better with infliximab plus methotrexate alone. We concluded from this article that repeated doses of infliximab in combination with methotrexate provide clinical benefit and halted the joint damage.

Ennio Giulio Favalli, Francesca Ingegnoli, Orazio De Lucia Gilberto Cincinelli Rolando Covid-19 infection and RA: faraway so close Autoimmune reviews 2020 In this article the author describes the viral infection risk in RA patient, with a particular focus on the knowledge about the current new pandemic and the use of anti-rheumatic drugs. We concluded that chloroquine and hydroxychloroquine are used for the management of COVID-19 infection and are also useful to prevent the course of infection in patient with RA taking them as a CsDMARDs

Elizabeth W Karlson, Lori B Chibnik, Peter Kraft, Jing Cul, Brendan T Keenan Bo Ding Cumulative association of 22 genetic variants with seropositive RA risk Annals of rheumatic diseases 2010 In this title, the author describes a cumulative score based on 22 validated genetic risk alleles for seropositive RA would identify high risk, asymptomatic individuals who might benefit from preventive interventions. We concluded that combination of 22 risk alleles into weighted GRS (genetic risk come) significantly stratifies individual of RA risk beyond clinical risk factor alone.

Katherine P Liao, Fina Kurreeman, Gang Li, Grant Duclos, Shawn Murphv Raul Guzman Association of auto antibodies, autoimmune risk alleles, and clinical diagnosis from electronic medical records in RA cases and non rheumatoid arthritis Arthritis and Rheumatism 2013 The main of this study is to assess association of auto antibodies with autoimmune risk alleles and with clinical diagnosis from electronic medical records (EMRS). We concluded that increase risk frequency of auto Abs in RA cases and non RA control are associated with the number of autoimmune risk alleles carried by an individual.

Rana Jahanbas-Esfahlan, Saeed Merzadi, Russel J Reiter, Khaled Seidi, Maryam Majidinia, Hossein Bannazadeh Baghi, Nasrin Khatami, Bahman Yousefi and Alitreza Sadeghpour Melatonin in regulation of inflammatory pathways in RA and osteoarthritis: involvement of circadian clock gene British journal of Pharmacology 2018 In this paper, the author carried out study on melatonin, a circadian control product is suggested as a potential link between circadian rhythms and joint disease including RA and OA. We concluded that anti-inflammatory actions of melatonin directly or indirectly block NF-k, B signaling and terminate the inflammatory response. It appears that restoring circadian rhythm alleviate the symptoms of both inflammatory joint disease especially in RA patients.

Anca I Catrina, Vijay Joshua, Lars Klareskog, Vivianne Malmstrom Mechanism involving triggering RA Immunological reviews 2016 Inh have a key role in this paper, the author discuss the highly reactive oxygen free radicals which have a key role in pathogenesis of disease. We conclude that RA patients showed a marked increase in ROS formation, protein oxidation, DNA damage and decrease in activity of antioxidant defense system which may contribute to tissue damage and hence to chronicity of the disease.

Katherine P.Liao, Dorothee Diogo and Robert M. Plenge Association between low density lipoprotein and RA genetic factor with low density lipoprotein levels in RA and non-RA Annals of rheumatoid diseases 2014 In this paper , the author determine the association of established LDL and RA genetic alleles with LDL levels in RA cases compared with non RA controls. We concluded that LDL alleles are associated with LDL levels in RA. RA alleles are associated with lower LDL levels in both RA cases and control. As RA cases carry more RA alleles, these finding suggest a genetic basis for epidemiological observations of lower LDL levels in RA.

Ashraf A. Ewis, Kazuya Kondo, Juwon Lee, Masaru Tsuyuguchi Infrequent ras oncogenes point mutations in lung cancer samples from chromate workers American journal of industrial medicine 2001 In this title, the author demonstrated that activation of ras genes due to point mutations in chromate-related lung cancer is a rare event. Ras oncogenes activated by point mutation donot have a major role in the process of tumorigenesis of chromate-related lung cancer.

Xiaomin Dng, Aiqun Ma, Lan Yang, Hao Hu, Bo Zhu, Dong Shang, Tianjun Chen, Yu Luo MicroRNA -26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells Cancer genetics 2012 In this title, the author describes the role of miRNAs in the regulation of various cancer especially lung cancer. We concluded that mi-26a plays an important role on anti-oncogenes in the molecular mechanism of HLC and could potentially be used for the treatment of lung cancer.

Stephen S.Hecht Tobacco smoke carcinogens and lung cancer Journal of the national cancer institute 21 July 1999 In this paper, author discusses mechanisms of DNA damage through free radical and reactive oxygen spp. He also evaluates how mutation in oncogenes and tumor suppressor gene shows their possible relationship to specific carcinogen and other factor as causes of lung cancer.

Sigal Gery, Naoki Komatsu, Norihiko Kawamata, Carl W. Miller,Renu K. Virk, Robert Mckenna, H. Phillip Koeffler Epigenetic silencing of the candidate tumor suppressor Per 1 in Non small cell lung cancer Clinical cancer research 2007 In this article, the author suggests a role for promoter methylation and histone deacetylation in the silencing of Per 1 expression in NSCLC. So any change in this process disrupts the expression of core clock gene and cellular pathway under circadian control.

Richard Doll Mortality from lung cancer in asbestos worker British Journal of industrial medicine 2000 This article demonstrate that lung cancer is specific industrial hazard of certain asbestos workers and average risk among employer working for 20 or more year have 10 times more risk of disease by the general population

Lisa Gallicchio, kristina Boyd, Genevieve Matanoski, Xuquanq Tao, Liwei Chen, Tram K Carotenoid and the risk of developing lung cancer The American Journal of clinical nutrition 2008 This article is conducted to review the association between caretenoid and lung cancer. We concluded that beta-carotene is not associated with the decrease in the risk of developing lung cancer. There is a inverse relationship between careened and lung cancer.

Kerathrine Carlsen, Anders Bonde Jensen, Erik Jacbsen, Mark Krasnik, Christoffer Johansen Psychosocial aspects of lung cancer Lung cancer 2005 This article deals that the person with lung cancer disease show not only the physical effect but also with the psychosocial aspects. We concluded that degree of depression can be reduced by psychosocial intervention.

B Martin, M Paesmans, J-P Sculier Ki-67 expression and patient survival in lung cancer British journal of cancer 2018 This article is carried out to suggest an association between Ki-67protein nd poor survivals in lung cancer patients. We concluded that expression of Ki=67 in patients with stages 1-3 NSCLC is a poor prognostic factor for survival. To make it a useful prognostic factor, a standardization of the immunohistochemistry technique is needed.

Chikako Kiyohara, Kouichi Yoshimasu, Koichi Takayama, Yoichi Nakanishi EPHX1 polymorphisms and the risk of lung cancer Journal of Epidemiology 2006 The aim of study is to overview and summarizes the available molecular epidemiologic studies of lung cancer of microsomal epoxide hydrolase 1(EPHX1). We concluded that EPHX1 enzyme acts as phase 1 enzyme in lung carcinogenesis. The low activity genotype of EPHX1 gene is associated with decrease risk of lung cancer among white population.

XY Zheng, YM Qi, YF Gao, XY Wang, MX Qi, XF Shi, XL An Expression and significance of membrane skeleton protein 4.1 family in lung cancer Chinese journal of cancer 2009 This study investigates the expression and significance of membrane skeleton protein 4.1 and its family members in human NSCLC. We concluded that protein 4.1s are weekly expressed in NSCLC tissue than normal tissue. The expression of proteins 4.1 members are related to tumor cell differentiation.

Roma Maguire, Constantina Papadopoulos, Grigorios Kotronoulas, Mhairi F Simpson A systematic review of supportive care needs of people living with lung cancer European Journal of Oncology 2013 The purpose of this review is to determine the supportive care need of people with lung cancer and to it slow and explore gaps in the assessment of needs emerging from this leterature. We concluded that the use of patient reports use as a tool of identifying and managing unmet needs in the patient population.

Susanna Cheng, William K Evans, Denise Stys-Norman, Frances A Shepherd. Lung cancer Chemotherapy for relapsed small cell lung cancer Journal of Thoracic Oncology 2007 This article evaluates chemotherapy option for patients with relapsed small cell lung cancer (SCLC). We concluded that evidence of clinical benefit of second line therapy SCLC is limited. Topotecan has a survival benefit and response but also has greater toxicity as compared to CAV.

Anne-Pascale Meert, Marianne Paesmans, Thierry Berghmans, Benoit Martin Celine Prophylactic cranial irradiation in lung cancer BMC cancer 2001 This review of literature is carried to determine the role of PCI in lung cancer. We concluded that PCI decreases brain metastasis incidence and improve survival in CR LC patient. The long term toxicity has not been prospectively evaluated.

Anthony J Alberg, Jean G Ford, Jonathan M Samet Epidemiology of lung cancer;ACCP evidence-based clinical practice guidelines CHEST 2007 This study is carried out to summarize the published literature that is concerned with the epidemiology of lung cancer. We concluded that lung cancer remain the leading cause of death in both men and women in the united state.

Ji-Ye Yin, Huang, Ying-Chun Zhao, Hong-Hao Zhou, Zhao-Qlan Liu Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer patients Plos one 2012 In this article the author determines the pharmacogenetics of platinum-based chemotherapy in NSCLC patients. We concluded that attention should be paid to MDR1 C3435T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.